Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21831666 | 1.00 | DPP8 (0.44) | DPP8CACNA1BCACNA1CCACNA2D1CACNB1 | |
| SCHEMBL21831897 | 0.87 | SLC6A9 (0.50) | CACNA1BCACNA1CCACNA2D1CACNB1 | |
| SCHEMBL21831898 | 0.87 | SLC6A9 (0.50) | CACNA1BCACNA1CCACNA2D1CACNB1 | |
| SCHEMBL26925513 | 0.86 | DPP8 (0.44) | DPP8CACNA1BCACNA1CCACNA2D1CACNB1 | |
| SCHEMBL26925507 | 0.86 | DPP8 (0.44) | DPP8CACNA1BCACNA1CCACNA2D1CACNB1 | |
| SCHEMBL25313898 | 0.83 | GPR119 (0.42) | DPP8MAPK1RAB9ADPP7MEN1 | |
| SCHEMBL28548497 | 0.83 | GPR119 (0.42) | DPP8MAPK1RAB9ADPP7MEN1 | |
| SCHEMBL25312428 | 0.83 | GPR119 (0.42) | DPP8MAPK1RAB9ADPP7MEN1 | |
| SCHEMBL21831122 | 0.83 | DPP8 (0.57) | DPP8CACNA1BCACNA1CCACNA2D1CACNB1 | |
| SCHEMBL21831121 | 0.83 | DPP8 (0.57) | DPP8CACNA1BCACNA1CCACNA2D1CACNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | DPP8 3019/4885CACNA1B 2544/4885CACNA1C 2775/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DPP8 3019/4885CACNA1B 2544/4885CACNA1C 2775/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DPP8 3019/4885CACNA1B 2544/4885CACNA1C 2775/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DPP8 3019/4885CACNA1B 2544/4885CACNA1C 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.